91影库

Journal News

From the journals: JLR

Andrea Pereyra
April 7, 2023

A promising oral compound to treat high cholesterol. Synchronizing liver metabolism with lactation. A new way to collect intestinal lymph. Read about papers on these topics recently published in the Journal of Lipid Research.

A promising oral compound to treat high cholesterol

Balance of plasma cholesterol levels is achieved by the liver, the main site of production and recycling, working with peripheral tissues, the main sites of uptake for utilization. Cholesterol flux is mediated by low-density lipoprotein, or LDL, and high-density lipoprotein, or HDL, and by their respective surface receptors.

A low-density lipoprotein cholesterol particle (yellow and purple) interacting with a low-density lipoprotein receptor (red) on the cell surface.
A low-density lipoprotein cholesterol particle (yellow and purple) interacting with a low-density lipoprotein receptor (red) on the cell surface.

Disturbances in plasma lipid homeostasis, such as elevation in LDL cholesterol, are linked to a higher risk of cardiovascular disease.

Alexandra K. Suchowerska of Nyrada Inc. in Australia and a group of international collaborators studied the effects of NYX-PCSK9i, a small-molecule inhibitor of the enzyme PCSK9, on plasma cholesterol levels. In the liver, PCSK9 binds to the LDL receptor in the surface of the hepatocyte, stimulating its internalization and degradation, thus impeding LDL cholesterol clearance and favoring accumulation in plasma. Their findings recently were in the Journal of Lipid Research.

The researchers showed that NYX-PCSK9i disrupts PCSK9–LDLR interaction, thus preventing LDL receptor degradation and maintaining LDL cholesterol uptake. Compound NYX-PCSK9i reduced plasma total cholesterol up to 57% and increased fecal cholesterol excretion when fed to mice that were altered genetically to have elevated cholesterol. Levels of HDL cholesterol were not changed.

Established cholesterol drugs such as statins often increase PCSK9 serum levels in humans. The study found that NYX-PCSK9i enhanced the effect of the anti-cholesterol drug atorvastatin, further reducing cholesterol up to a total of 65% and setting a precedent for future clinical trials.

More research is needed to confirm the mechanism by which NYX-PCSK9i inhibits the PCSK9 enzyme and preserves LDL cholesterol clearance by the liver.

Synchronizing liver metabolism with lactation

After a person gives birth to a baby, their brain communicates with the metabolic organs by means of prolactin to ensure nutrients get to the mammary gland for milk production. The baby’s suckling creates a positive feedback mechanism that keeps prolactin levels high and influences parental metabolism to support milk production.

In human milk, lipids contribute up to 50% of the energy content, in part via triacylglycerols synthesized in the liver. However, researchers do not yet fully understand the mechanism that protects a lactating person from excessive liver fat accumulation, known as hepatic steatosis.

In a recent in the Journal of Lipid Research, Maria A. Ramos–Rom谩n and colleagues from the University of Texas Southwestern Medical Center and other institutions across the U.S. studied the relationship between liver metabolism and lactation six weeks after birth.

Compared with formula-feeding parents, they found that lactating parents had lower fasting plasma insulin with greater adipose tissue insulin sensitivity, higher endogenous glucose production and higher high-density lipoprotein cholesterol.

Parents with elevated prolactin during lactation had lower intrahepatic triacylglycerol levels, and fatty acids were readily shuffled from the liver into the circulation as very low density lipoprotein triglyceride particles, thus preventing accumulation, the researchers found. Furthermore, lactating parents had increased uptake of these particles by peripheral tissues, resulting in beneficially lower plasma levels.

A new way to collect intestinal lymph

Intestinal trafficking of nutrients, drugs and cells follows one of two routes depending on the physicochemical characteristics of the cargo in question. Once inside an absorbent cell in the colon, cargo can reach the general circulation directly via the portal vein or indirectly via mesenteric lymphatic vessels. The latter route is important for the absorption of dietary lipids, in particular long-chain free fatty acids and triacylglycerols, packed into lipoproteins such as chylomicrons.

In a recent in the Journal of Lipid Research, Nikolaos Dedousis and colleagues at the University of Pittsburgh describe a new technique to collect mesenteric lymph from mice and to isolate intestinal chylomicrons and immune cells.

The authors modified an existing two-day technique to a single-day surgery with higher survival and greater lymph retrieval in mice. A cannula was placed in the duodenum to infuse lipids, and another cannula was placed in the mesenteric lymph duct to collect lymph every hour for six hours after feeding.

The team analyzed the mesenteric lymph isolated by this technique and found that secretion of triacylglycerols peaked three hours after the lipid infusion and that levels were three times higher than the two-day technique. They also found immune cells positive for CD45 and CD4 markers and regulatory T cells in the retrieved mesenteric lymph.

Enjoy reading 91影库Today?

Become a member to receive the print edition four times a year and the digital edition monthly.

Learn more
Andrea Pereyra

Andrea S. Pereyra is a postdoctoral scholar at the East Carolina Diabetes and Obesity Institute. She earned her M.D./Ph.D. at Universidad Nacional de La Plata in Buenos Aires, Argentina. 

Get the latest from 91影库Today

Enter your email address, and we鈥檒l send you a weekly email with recent articles, interviews and more.

Latest in Science

Science highlights or most popular articles

Hope for a cure hangs on research
Essay

Hope for a cure hangs on research

July 17, 2025

Amid drastic proposed cuts to biomedical research, rare disease families like Hailey Adkisson鈥檚 fight for survival and hope. Without funding, science can鈥檛 鈥渃atch up鈥 to help the patients who need it most.

Before we鈥檝e lost what we can鈥檛 rebuild: Hope for prion disease
Feature

Before we鈥檝e lost what we can鈥檛 rebuild: Hope for prion disease

July 15, 2025

Sonia Vallabh and Eric Minikel, a husband-and-wife team racing to cure prion disease, helped develop ION717, an antisense oligonucleotide treatment now in clinical trials. Their mission is personal 鈥 and just getting started.

Defeating deletions and duplications
News

Defeating deletions and duplications

July 11, 2025

Promising therapeutics for chromosome 15 rare neurodevelopmental disorders, including Angelman syndrome, Dup15q syndrome and Prader鈥揥illi syndrome.

Using 'nature鈥檚 mistakes' as a window into Lafora disease
Feature

Using 'nature鈥檚 mistakes' as a window into Lafora disease

July 10, 2025

After years of heartbreak, Lafora disease families are fueling glycogen storage research breakthroughs, helping develop therapies that may treat not only Lafora but other related neurological disorders.

Cracking cancer鈥檚 code through functional connections
News

Cracking cancer鈥檚 code through functional connections

July 2, 2025

A machine learning鈥揹erived protein cofunction network is transforming how scientists understand and uncover relationships between proteins in cancer.

Gaze into the proteomics crystal ball
In-person Conference

Gaze into the proteomics crystal ball

July 1, 2025

The 15th International Symposium on Proteomics in the Life Sciences symposium will be held August 17鈥21 in Cambridge, Massachusetts.